Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
07/29/2008
Trade Name:
Cancidas
Generic or Proper Name (*):
caspofungin
Indications Studied:
Empirical therapy for presumed fungal infections in febrile, neutropenic patients; Candidemia and certain Candida infections; Esophageal Candidiasis; Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies
Therapeutic Category:
Antifungal
Ages Studied:
2 - 17 years
Study #:
1
Study Type:
Safety/Pharmacokinetic
Study Design:
Open Label/Traditional Pharmacokinetic/Dose Response(1/3)
No Patients:
39
No Centers:
8
No Countries:
1
BPCA(B), PREA(P):
B, P
Asian:
0
Black:
3
Other:
12
White:
38
Native Hawaiian or Pacific Islander:
8
American Indian/Alaska Native:
5
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
-
-